AEGON ASSET MANAGEMENT UK Plc Has $32.01 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

AEGON ASSET MANAGEMENT UK Plc increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 285,817 shares of the biopharmaceutical company's stock after purchasing an additional 18,343 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc's holdings in Gilead Sciences were worth $32,012,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in GILD. Unigestion Holding SA acquired a new stake in shares of Gilead Sciences in the first quarter valued at approximately $4,325,000. HBW Advisory Services LLC increased its position in Gilead Sciences by 8.4% during the first quarter. HBW Advisory Services LLC now owns 3,365 shares of the biopharmaceutical company's stock worth $377,000 after buying an additional 262 shares in the last quarter. Merit Financial Group LLC lifted its position in shares of Gilead Sciences by 48.3% in the first quarter. Merit Financial Group LLC now owns 29,229 shares of the biopharmaceutical company's stock valued at $3,275,000 after acquiring an additional 9,522 shares in the last quarter. Milestone Asset Management LLC boosted its stake in shares of Gilead Sciences by 170.9% during the first quarter. Milestone Asset Management LLC now owns 60,343 shares of the biopharmaceutical company's stock valued at $6,761,000 after acquiring an additional 38,066 shares during the last quarter. Finally, Fragasso Financial Advisors Inc purchased a new stake in Gilead Sciences during the 1st quarter worth about $208,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the sale, the chief executive officer now owns 620,268 shares in the company, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 60,929 shares of company stock valued at $6,748,980 over the last ninety days. Insiders own 0.27% of the company's stock.

Gilead Sciences Price Performance

NASDAQ:GILD traded down $0.31 during midday trading on Wednesday, hitting $109.02. 7,963,204 shares of the stock were exchanged, compared to its average volume of 7,734,649. The company has a market capitalization of $135.61 billion, a price-to-earnings ratio of 294.65, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The business has a 50-day moving average price of $105.45 and a two-hundred day moving average price of $101.10.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company's quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.32) EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.90%. Gilead Sciences's payout ratio is currently 66.53%.

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. The Goldman Sachs Group raised their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Piper Sandler upped their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Finally, Bank of America lifted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.